Full Press Release Details
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109.
MBX
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
Key Takeaway: MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+163%
120-day peak, hindsight
Typical move
5.3%
average across 7 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
MBX 4291
Phase 1 · Obesity